Fig. 3: Cumulative occurrence of intracranial hemorrhage (ICH) by antithrombotic treatment group. Data from the enoxaparin group from the ASSENT-3 PLUS trial were compared with those from the ASSENT-3 trial (p = 0.01), and with data from the unfractionated heparin groups of the ASSENT-3 PLUS (p = 0.047) and ASSENT-3 (p = 0.004) trials, by means of the log–rank test.